| 2026-05-27 | Press release | Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European As |
| 2026-05-21 | Press release | Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented |
| 2026-05-14 | Press release | Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American |
| 2026-04-29 | Press release | Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study |
| 2026-04-28 | Press release | Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual M |
| 2026-04-22 | Press release | Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study o |
| 2026-04-15 | Press release | Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries |
| 2026-04-08 | Press release | Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference |
| 2026-03-12 | Press release | Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update |
| 2026-03-11 | Press release | Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program |
| 2026-03-10 | Press release | Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Ben |
| 2026-03-09 | Press release | Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 |
| 2026-03-09 | Press release | Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Inves |
| 2026-03-04 | Presentation | PBGENE-DMD gene editing treatment leads to safe and long-term functional improvement in humanized DMD-disease mouse mode |
| 2026-03-02 | Press release | Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclero |
| 2026-02-18 | Press release | Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference |
| 2026-02-11 | Press release | Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD |
| 2026-01-12 | Press release | Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBG |
| 2025-12-09 | Presentation | PBGENE-HBV, a First-in-class Gene Editing Therapy for Chronic Hepatitis B, Demonstrates Safety and Antiviral Activity Ac |
| 2025-11-19 | Press release | Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 |
| 2025-11-10 | Press release | Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerab |
| 2025-11-10 | Press release | Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants |
| 2025-10-14 | Press release | Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025 |
| 2025-10-09 | Press release | Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gen |
| 2025-10-07 | Press release | Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial |
| 2025-09-30 | Press release | Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World |
| 2025-09-23 | Presentation | Treatment with PBGENE-DMD results in durable improvements in muscle function over time through increased dystrophin expr |
| 2025-09-12 | Press release | Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition |
| 2025-09-08 | Press release | Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status |
| 2025-08-06 | Press release | Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-H |
| 2025-07-23 | Press release | Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrop |
| 2025-07-16 | Press release | Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editin |
| 2025-06-25 | Press release | Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscu |
| 2025-05-14 | Press release | Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre- |
| 2025-05-09 | Presentation | ARCUS-Mediated Excision of Exons 45-55 of the Human Dystrophin Gene using PBGENE-DMD Leads to Durable Muscle Function Im |
| 2025-05-08 | Presentation | Excision of the C9orf72 Hexanucleotide Repeat Expansion Using a Dual-ARCUS Gene Editing Approach Delivered by a Single A |
| 2025-05-08 | Press release | Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 |
| 2025-05-07 | Presentation | Initial safety data from ELIMINATE-B, the first clinical trial of a gene editing treatment for chronic hepatitis B. |
| 2025-05-07 | Press release | Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE |
| 2025-05-01 | Press release | Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene |